Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113).

ESMO Gastrointest Oncol · 2026 · PMC13080808 · PMID 41994030

Europe PMC DOI

hedged sentence

0.1798

closest p · 3.6× alpha

0.1798

boldest claim

The sentences

showed a trendP = 0.1798not close (p > 0.1)

Patients with baseline cGDF-15 levels above 0.8 ng/ml and increasing cGDF-15 levels after ICT showed a trend of a worse OS compared with patients with stable or decreasing cGDF-15 levels [mOS 14.13 months ( n = 29) versus 22.21 months ( n = 13), respectively, P = 0.1798].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.